EMPAVELI (pegcetacoplan) is the first approved treatment for C3G or primary IC-MPGN for patients 12 years and older in Canada Approval supported by Phase 3 52-week VALIANT study demonstrated reduced ...
EMPAVELI®(pegcetacoplan) is the first approved treatment for C3G or primary IC-MPGN for patients 12 years and older in CanadaApproval supported ...
Bringing together Biogen and Apellis’ commercialization capabilities will maximize the potential of both EMPAVELI ® and SYFOVRE ®, while Apellis’ talent and expertise will accelerate Biogen’s entry ...
Researches made major strides toward the creation of artificial kidney tissue by demonstrating an undiscovered mechanism behind kidney development and a novel technique for culturing kidney cells, ...
When Chrissi Anderson went to the hospital for a burst appendix, a CT scan uncovered a shocking extra finding: She had a 1-pound kidney stone lurking in her body. “I couldn't believe it. It was huge ...
A transplant is often preferable to dialysis. While dialysis is a life-saving measure, it’s a lifetime commitment, and it has potential risks and complications. Your doctor determines whether you’re ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results